PMID- 22278047
OWN - NLM
STAT- MEDLINE
DCOM- 20120820
LR  - 20220408
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 33
IP  - 4
DP  - 2012 May
TI  - Statins, inflammation and deep vein thrombosis: a systematic review.
PG  - 371-82
LID - 10.1007/s11239-012-0687-9 [doi]
AB  - Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) and 
      pulmonary embolism. The 2009 JUPITER trial showed a significant decrease in DVT 
      in non-hyperlipidemic patients, with elevated C-reactive protein (CRP) levels, 
      treated with rosuvastatin. The effects of statins on thrombosis are unclear, 
      prompting this literature review. A literature search was performed (1950 to 
      February 2011) with MEDLINE, EMBASE, and PUBMED databases including the following 
      keywords: "statins", "hydroxymethylglutaryl-CoA reductase inhibitors", "VTE", 
      "PE", "DVT", and either "anti-coagulation" or "inflammation". Editorials, 
      reviews, case reports, meta-analysis and duplicates were excluded. Inflammatory 
      biomarkers of DVT, include interleukin (IL)-6, CRP, IL-8, and monocyte 
      chemotactic protein 1 (MCP-1). Statin therapy reduces IL-6 expression of CRP and 
      MCP-1, usually elevated in VTE. Reduction of IL-6 induced MCP-1 has been linked 
      to vein wall fibrosis, promoting post thrombotic syndrome (PTS) and recurrent DVT 
      in patients. Also, our review suggests that the anti-thrombotic effects are 
      likely exhibited through the anti-inflammatory properties of statins. This work 
      supports that statin therapy has the ability to decrease the incidence and 
      recurrence of VTE and the potential to decrease PTS. This is mainly due to the 
      anti-inflammatory effects of statins and may explain why normolipidemic patients, 
      with elevated CRP, appear to have the greatest reduction in VTE. Given their low 
      risk of bleeding, statins have the potential to serve as a safe adjunctive 
      pharmacological therapy to current treatments in select patients with VTE, 
      however further investigations into this concept are needed and essential.
FAU - Rodriguez, April L
AU  - Rodriguez AL
AD  - Department of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular 
      Research Laboratories, School of Medicine, University of Michigan, 1150 W. 
      Medical Center Drive, Ann Arbor, MI 48109, USA.
FAU - Wojcik, Brandon M
AU  - Wojcik BM
FAU - Wrobleski, Shirley K
AU  - Wrobleski SK
FAU - Myers, Daniel D Jr
AU  - Myers DD Jr
FAU - Wakefield, Thomas W
AU  - Wakefield TW
FAU - Diaz, Jose A
AU  - Diaz JA
LA  - eng
GR  - P01 HL089407/HL/NHLBI NIH HHS/United States
GR  - P01 HL089407-01A1/HL/NHLBI NIH HHS/United States
GR  - 1P01HL089407/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PT  - Systematic Review
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Cytokines)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 2.3.3.10 (Hydroxymethylglutaryl-CoA Synthase)
SB  - IM
MH  - C-Reactive Protein/metabolism
MH  - Cytokines/metabolism
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use
MH  - Hydroxymethylglutaryl-CoA Synthase/metabolism
MH  - MEDLINE
MH  - Pulmonary Embolism/*drug therapy/metabolism
MH  - Venous Thromboembolism/*drug therapy/metabolism
MH  - Venous Thrombosis/*drug therapy/metabolism
PMC - PMC3338886
MID - NIHMS351125
EDAT- 2012/01/27 06:00
MHDA- 2012/08/21 06:00
PMCR- 2012/05/01
CRDT- 2012/01/27 06:00
PHST- 2012/01/27 06:00 [entrez]
PHST- 2012/01/27 06:00 [pubmed]
PHST- 2012/08/21 06:00 [medline]
PHST- 2012/05/01 00:00 [pmc-release]
AID - 10.1007/s11239-012-0687-9 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2012 May;33(4):371-82. doi: 10.1007/s11239-012-0687-9.